$6.29
0.396.61%
At Close: -
$6.29
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Foghorn Therapeutics
FHTXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Foghorn Therapeutics (NASDAQ:FHTX) Stock, Analyst Ratings, Price Targets, Forecasts
Foghorn Therapeutics Inc has a consensus price target of $14.5 based on the ratings of 6 analysts. The high is $20 issued by HC Wainwright & Co. on May 7, 2024. The low is $6 issued by Morgan Stanley on November 13, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Wedbush on May 7, 2024, May 1, 2024, and April 10, 2024, respectively. With an average price target of $17.67 between HC Wainwright & Co., HC Wainwright & Co., and Wedbush, there's an implied 180.87% upside for Foghorn Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
Morgan Stanley
Goldman Sachs
BMO Capital
1calculated from analyst ratings
Analyst Ratings for Foghorn Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/07/2024 | Buy Now | 217.97% | HC Wainwright & Co. | Andrew Fein | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/01/2024 | Buy Now | 217.97% | HC Wainwright & Co. | Andrew Fein | → $20 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 106.68% | Wedbush | Robert Driscoll | — | Reiterates | Outperform → Outperform | Get Alert |
| 04/10/2024 | Buy Now | 217.97% | HC Wainwright & Co. | Andrew Fein | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | Buy Now | 106.68% | Wedbush | Robert Driscoll | → $13 | Reiterates | Outperform → Outperform | Get Alert |
| 11/13/2023 | Buy Now | -4.61% | Morgan Stanley | Vikram Purohit | $10 → $6 | Maintains | Equal-Weight | Get Alert |
| 08/07/2023 | Buy Now | 217.97% | HC Wainwright & Co. | Andrew Fein | → $20 | Reiterates | Buy → Buy | Get Alert |
| 07/06/2023 | Buy Now | 58.98% | Morgan Stanley | Vikram Purohit | $13 → $10 | Maintains | Equal-Weight | Get Alert |
| 06/29/2023 | Buy Now | 202.07% | Goldman Sachs | Paul Choi | $21 → $19 | Maintains | Buy | Get Alert |
| 06/28/2023 | Buy Now | 217.97% | HC Wainwright & Co. | Andrew Fein | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/08/2023 | Buy Now | 217.97% | HC Wainwright & Co. | Andrew Fein | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2023 | Buy Now | 122.58% | Wedbush | Robert Driscoll | $15 → $14 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | 217.97% | HC Wainwright & Co. | Andrew Fein | $25 → $20 | Maintains | Buy | Get Alert |
| 04/25/2023 | Buy Now | 202.07% | BMO Capital | Etzer Darout | $20 → $19 | Maintains | Outperform | Get Alert |
| 04/25/2023 | Buy Now | 138.47% | Wedbush | Robert Driscoll | $20 → $15 | Maintains | Outperform | Get Alert |
| 03/28/2023 | Buy Now | 58.98% | B of A Securities | Chi Fong | → $10 | Initiates | → Buy | Get Alert |
| 03/10/2023 | Buy Now | 297.46% | HC Wainwright & Co. | Andrew Fein | → $25 | Reiterates | → Buy | Get Alert |
| 03/10/2023 | Buy Now | 217.97% | Wedbush | Robert Driscoll | $25 → $20 | Maintains | Outperform | Get Alert |
| 01/05/2023 | Buy Now | 217.97% | BMO Capital | Etzer Darout | → $20 | Initiates | → Outperform | Get Alert |
| 11/21/2022 | Buy Now | 122.58% | Morgan Stanley | Vikram Purohit | $15 → $14 | Maintains | Equal-Weight | Get Alert |
| 08/24/2022 | Buy Now | 138.47% | Morgan Stanley | Vikram Purohit | $25 → $15 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/10/2022 | Buy Now | 297.46% | HC Wainwright & Co. | Andrew Fein | $18 → $25 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | 233.86% | Goldman Sachs | Paul Choi | $30 → $21 | Maintains | Buy | Get Alert |
| 05/23/2022 | Buy Now | 297.46% | Morgan Stanley | Vikram Purohit | $26 → $25 | Maintains | Overweight | Get Alert |
| 05/20/2022 | Buy Now | 186.17% | HC Wainwright & Co. | Andrew Fein | $25 → $18 | Maintains | Buy | Get Alert |
| 12/15/2021 | Buy Now | 313.35% | Morgan Stanley | Vikram Purohit | — | Maintains | Overweight | Get Alert |
| 11/22/2021 | Buy Now | 297.46% | HC Wainwright & Co. | Andrew Fein | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Foghorn Therapeutics (FHTX) stock?
The latest price target for Foghorn Therapeutics (NASDAQ:FHTX) was reported by HC Wainwright & Co. on May 7, 2024. The analyst firm set a price target for $20.00 expecting FHTX to rise to within 12 months (a possible 217.97% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Foghorn Therapeutics (FHTX)?
The latest analyst rating for Foghorn Therapeutics (NASDAQ:FHTX) was provided by HC Wainwright & Co., and Foghorn Therapeutics reiterated their buy rating.
When was the last upgrade for Foghorn Therapeutics (FHTX)?
There is no last upgrade for Foghorn Therapeutics
When was the last downgrade for Foghorn Therapeutics (FHTX)?
The last downgrade for Foghorn Therapeutics Inc happened on August 24, 2022 when Morgan Stanley changed their price target from $25 to $15 for Foghorn Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Foghorn Therapeutics (FHTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Foghorn Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Foghorn Therapeutics was filed on May 7, 2024 so you should expect the next rating to be made available sometime around May 7, 2025.
Is the Analyst Rating Foghorn Therapeutics (FHTX) correct?
While ratings are subjective and will change, the latest Foghorn Therapeutics (FHTX) rating was a reiterated with a price target of $20.00 to $20.00. The current price Foghorn Therapeutics (FHTX) is trading at is $6.29, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.